 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Nivolumab combined with Ipilimumab in the treatment of advanced metaplastic breast cancer

Clin Cancer Res: Nivolumab combined with Ipilimumab in the treatment of advanced metaplastic breast cancer

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

bisacodyl 10 mg

mepron side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Metaplastic breast cancer (MpBC) is a rare invasive primary breast malignant tumor, accounting for about 0.

Breast cancer

This article reports the S1609 cohort study on this rare tumor: the outcome of advanced MpBC treatment with ipilimumab + nivolumab

The study is a prospective, open-label, multicenter Phase 2 (two-phase) clinical trial.

The biggest change in the tumor

Overall, a total of 17 evaluable patients were recruited, with a median age of 60 years (range 26-85); the median number of previous treatments was two (range 0-5)

The median PFS and OS were 2 months and 12 months, respectively

Overall survival rate and progression-free survival rate

Eleven (65%) patients experienced side effects (AE), including one grade 5 AE

immunity

In summary, no new safety issues occurred in patients with MpBC refractory to advanced chemotherapy when combined with ipilimumab and nivolumab, and an objective response rate of 18% as the primary endpoint was achieved

There are no new safety issues when combined treatment with ipilimumab and nivolumab in advanced chemotherapy-refractory MpBC patients, and an objective response rate of 18% as the primary endpoint is achieved .

Original source:

Adams Sylvia, Othus Megan, Patel Sandip Pravin et al.

Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.